Taken together, we found that nRCT significantly increases the percentage of rectal cancer-infiltrating slanMo locally expressing iNOS and TNF-α, which can either mediate tumor-promoting or antitumor effects and may affect the efficacy of nRCT in rectal cancer patients. The gene discussed is NOS2; the disease is rectal cancer.